Alzheimer drug trials grow but cures remain elusive
The number of clinical trials testing Alzheimer’s drugs is rising steadily. Yet approved treatments remain few. Researchers reviewed 192 ongoing trials to map where the field stands.
Alzheimer’s disease is the most common form of dementia, affecting hundreds of millions of people worldwide. The number of available drugs is still small. Recent years have brought a handful of treatments that remove amyloid plaques (protein deposits in the brain), but their impact on daily functioning remains modest. Expectations for new generations of drugs are therefore high.
According to the study, an annual review of ongoing clinical trials, 158 drugs are currently being tested across 192 trials. That represents an increase from previous years. Growth is concentrated in early research phases, suggesting scientists are now exploring a broader range of molecular targets.
What is being tested
Alongside the familiar amyloid- and tau-targeting drugs (aimed at the two most studied protein structures in Alzheimer’s), a growing share of trials focuses on inflammatory processes, energy metabolism in brain cells, and the gut-brain connection. This reflects a wider shift in the field: Alzheimer’s is increasingly viewed as a disease with multiple causes rather than a single molecular culprit.
The demographic outlook is sobering. The number of people with Alzheimer’s is projected to rise sharply as populations age. That increases the urgency of finding effective treatments.
The gap between lab and clinic remains wide
More trials are running, but only a small fraction of drug candidates reach approval. Most fail in phase two or three of clinical testing, when the drug is first evaluated in larger groups of people. The researchers note that better patient selection in early phases may be one key to improving that success rate.